[vc_row][vc_column offset=”vc_col-lg-offset-1 vc_col-lg-10″][vc_column_text]

Posters & Presentations

[/vc_column_text][vc_column_text]

Crohn’s & Colitis Congress 2024

[/vc_column_text][vc_column_text]

Encouraging Efficacy of VT1021 in Preclinical Models of DSS-Induced Colitis

>> View Poster[/vc_column_text][vc_column_text]

[/vc_column_text][vc_column_text]

ASCO 2023

[/vc_column_text][vc_column_text]

Immune Profiling in Recurrent Glioblastoma Subjects Treated with VT1021 in a Phase I/II Expansion Study

>> View Poster[/vc_column_text][vc_column_text]

[/vc_column_text][vc_column_text]

SNO 2021

[/vc_column_text][vc_column_text]

Clinical efficacy and biomarker assessment of VT1021, a CD36/CD47 dual-targeting agent, in recurrent glioblastoma

>> View Poster[/vc_column_text][vc_column_text]

[/vc_column_text][vc_column_text]

SITC 2021

[/vc_column_text][vc_column_text]

Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers

>> View Poster
>> Presentation Audio

Development of Thrombospondin-1 as a clinical pharmacodynamic biomarker for VT1021, a first-in-class therapeutic agent that reprograms the tumor microenvironment.

>> View Poster
>> Presentation Audio[/vc_column_text][vc_column_text]

[/vc_column_text][vc_column_text]

ESMO 2019

[/vc_column_text][vc_column_text]

Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumor

>> View Poster[/vc_column_text][vc_column_text]

[/vc_column_text][vc_column_text]

ASCO 2019

[/vc_column_text][vc_column_text]

A phase 1 open label study evaluating VT1021 in patients with advanced solid tumors

>> View Poster[/vc_column_text][/vc_column][/vc_row]